Annexon, Inc. (ANNX)

NASDAQ: ANNX · IEX Real-Time Price · USD
+0.75 (35.71%)
At close: May 26, 2023, 4:00 PM
-0.03 (-1.05%)
Pre-market: May 30, 2023, 7:52 AM EDT

Company Description

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders.

The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration.

Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis.

The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy.

In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications.

The company was incorporated in 2011 and is headquartered in Brisbane, California.

Annexon, Inc.
Annexon logo
Country United States
Founded 2011
IPO Date Jul 24, 2020
Industry Biotechnology
Sector Healthcare
Employees 80
CEO Douglas Love Esq., J.D.

Contact Details

1400 Sierra Point Parkway, Bldg C, Suite 200
Brisbane, California 94005
United States
Phone (650)-822-5500

Stock Details

Ticker Symbol ANNX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001528115
CUSIP Number 03589W102
ISIN Number US03589W1027
Employer ID 27-5414423
SIC Code 2834

Key Executives

Name Position
Douglas Love J.D., Esq. Chief Executive Officer, President and Director
Dr. Larry C. Mattheakis Ph.D. Executive Vice President and Chief Scientific Officer
Dr. Ted Yednock Ph.D. Executive Vice President, Chief Innovation Officer and Chairman of the Scientific Advisory Board
Dr. Arnon Rosenthal Ph.D. Founder
Jennifer Lew Executive Vice President and Chief Financial Officer
Miriam Mason Senior Vice President of Corporate Communications
Michael Overdorf M.B.A. Executive Vice President and Chief Business Officer
Henk-Andre Kroon M.D. Senior Vice President of Translational Medicine
Mirella Villa Del Toro Secretary

Latest SEC Filings

Date Type Title
May 25, 2023 8-K Current Report
May 8, 2023 8-K Current Report
May 8, 2023 10-Q Quarterly Report
Apr 25, 2023 ARS Filing
Apr 25, 2023 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2023 DEF 14A Other definitive proxy statements
Mar 13, 2023 8-K Current Report
Mar 6, 2023 S-8 Securities to be offered to employees in employee benefit plans
Mar 6, 2023 8-K Current Report
Mar 6, 2023 10-K Annual Report